RecruitingPhase 4NCT04180397

Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Goal Directed Fluid Removal With Furosemide in Intensive Care Patients With Fluid Overload - A Randomised, Blinded, Placebo-controlled Trial (GODIF).


Sponsor

Morten H. Bestle

Enrollment

1,000 participants

Start Date

Aug 17, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This study evaluates the benefits and harms of goal directed fluid removal with furosemide versus placebo in critical ill adult patients with fluid overload in the intensive care unit. Half of the patients will receive furosemide and the other half placebo. The treatment will continue until the excess fluid is excreted.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Acute admission to the intensive care unit.
  • Age ≥ 18 years of age
  • Fluid overload ≥ 5% of ideal body weight. If possible, all fluids administered before admission to the intensive care unit are to be included in the calculation of cumulative fluid balance.
  • Clinical stable (minimum criteria: MAP > 50 mmHg and maximum infusion of 20 microgram/kg/minute of noradrenaline and lactate < 4.0 mmol/L)

Exclusion Criteria12

  • Known allergy to furosemide or sulphonamides.
  • Known pre-hospitalization advanced chronic kidney disease (eGFR < 30 mL/minute/1.73 m\^2 or chronic RRT).
  • Ongoing renal replacement therapy.
  • Anuria > 6 hours.
  • Rhabdomyolysis with indication for forced diuresis
  • Ongoing life-threatening bleeding as these patients need specific fluid/blood product strategies.
  • Acute burn injury of more than 10% of the body surface area as these patients need a specific fluid strategy.
  • Severe dysnatremia (p-Na < 120 or > 155 mmol/L) as these patients need a specific fluid strategy.
  • Severe hepatic failure as per the clinical team.
  • Patients undergoing forced treatment.
  • Fertile women (women < 50 years) with positive urine human chorionic gonadotropin (hCG) or plasma-hCG.
  • Consent not obtainable as per the model approved for the specific trial site.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFurosemide

Furosemide 10 mg/ml for injection/infusion

DRUGIsotonic saline

Isotonic saline used as placebo (injection/infusion)


Locations(24)

Department of Intensive Care, Liverpool Hospital

Sydney, Australia

Department of Intensive Care, Sygehus Sønderjylland Aabenraa

Aabenraa, Denmark

Departmen of Intensive Care

Aalborg, Denmark

Department of Intensive Care, Aarhus University Hospital

Aarhus, Denmark

Department of Intensive Care, Rigshospitalet

Copenhagen, Denmark

Departement of Intensive Care, Gentofte Hospital

Gentofte Municipality, Denmark

Department of Intensive Care, Herlev Hospital

Herlev, Denmark

Department of Intensive Care, Regionshospital Gødstrup

Herning, Denmark

Department of Intensive Care, Nordsjællands hospital

Hillerød, Denmark

Department of Intensive Care, Regionshospital Nordjylland Hjørring

Hjørring, Denmark

Department of Intensive Care

Kolding, Denmark

Department of Intensive Care, Zealand University hospital

Køge, Denmark

Department of Intensive Care

Odense, Denmark

Department of Intensive Care, Regionshospitalet Randers

Randers, Denmark

Department of Intensive Care, University Hospital Zealand, Roskilde

Roskilde, Denmark

Department of Intensive Care

Vejle, Denmark

Regionshospitalet Viborg

Viborg, Denmark

Department of Intensive Care, Tampere University Hospital

Tampere, Finland

Department of Intensive Care

Turku, Finland

Department of Intensive Care, Landspitali National University Hospital of Iceland

Reykjavik, Iceland

Department of Critical Care, University Medical Center Groningen

Groningen, Netherlands

Department of Intensive Care, Ålesund Sjukehus

Ålesund, Norway

Department of Intensive Care, Stavanger University Hospital

Stavanger, Norway

Department of Intensive Care, Inselspital

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04180397


Related Trials